News | November 07, 2014

Lantheus Medical Imaging, Shine Medical Announce Mo-99 Supply Agreement

Agreement supports U.S. efforts to ensure future reliable supply of most widely used imaging tracer

November 7, 2014 — Lantheus Medical Imaging Inc. and Shine Medical Technologies Inc. announced that the companies have entered into a strategic agreement for the future supply of molybdenum-99 (Mo-99). The supply agreement marks Lantheus’ first with a prospective United States supplier of Mo-99.

Under the terms of the supply agreement, Shine will provide Mo-99 produced using its proprietary low-enriched uranium (LEU)-solution technology for use in Lantheus’ TechneLite (Technetium Tc99m Generator) generators once Shine’s facility becomes operational and receives all necessary regulatory approvals, which Shine estimates will occur in early 2018. Mo-99 is the parent isotope of technetium-99m (Tc-99m), an essential tracer in a variety of diagnostic tests and the most widely used isotope in nuclear medicine.

Currently, Lantheus receives Mo-99 from four of the five major processors and seven of the eight associated reactors. As the medical imaging community moves toward LEU-based Mo-99 supply, Lantheus' LEU TechneLite generator and gradual conversion to a 100-percent LEU-derived Mo-99 supply chain ensures that Lantheus customers will have access to Tc-99m now and in the future.

For more information: www.lantheus.com

Related Content

Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging | September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
German Team Optimizing Therapy Planning for Cancers of the Liver
News | Interventional Radiology | August 29, 2017
Radioembolization is a therapy method used for liver tumors that are uncurable with surgery or chemotherapy. Thorough...
Sponsored Content | Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Sponsored Content | Videos | Nuclear Imaging | August 24, 2017
Randy Thompson, M.D., attending cardiologist, St.
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Overlay Init